Whitehawk Therapeutics (WHWK) Cash & Current Investments (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Cash & Current Investments data on file, last reported at $123.0 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $123.0 million, down 46.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.0 million (down 46.75% YoY), and the FY2025 annual result was $145.7 million, up 208.44% from the prior year.
• Cash & Current Investments slipped to $123.0 million in Q1 2026 per WHWK's latest filing, from $145.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $287.3 million in Q3 2025 and troughed at $47.2 million in Q4 2024.
• A 5-year average of $138.8 million and a median of $129.8 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments tumbled 56.6% in 2024, then soared 358.75% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $172.6 million in 2022, then slumped by 36.92% to $108.8 million in 2023, then plunged by 56.6% to $47.2 million in 2024, then surged by 208.44% to $145.7 million in 2025, then dropped by 15.55% to $123.0 million in 2026.
• Business Quant data shows WHWK's Cash & Current Investments at $123.0 million in Q1 2026, $145.7 million in Q4 2025, and $287.3 million in Q3 2025.